Will the BEAT-ROP study results really beat ROP?

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 12, 2011, Pages 9288-9289

  Raizada, Seemant ^a   Al Kandari, Jamal ^a   Al Sabti, Khalid ^a  

^a IBN SINA HOSPITAL   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN; SEMAXANIB; SOMATOMEDIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

BLEEDING; DRUG EFFICACY; DRUG SAFETY; EPIRETINAL MEMBRANE; HUMAN; HYPERTENSION; HYPOXIA; LETTER; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RETINA DETACHMENT; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; THROMBOEMBOLISM; ANIMAL; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; MICE; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856173126     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8479     Document Type: Letter

References (13)

1. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP cooperative group: efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
2. Wani VB, Kumar N, Sabti K, et al. Results of screening for retinopathy of prematurity in a large nursery in Kuwait: incidence and risk factors. Indian J Ophthalmol. 2010;58(3):204-208.
3. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380(6573):439-442.
4. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-1228.
5. Grimm C, Wenzel A, Groszer M, et al. HIF-1 induced erythropoietin in the hypoxic retina protects against light induces retinal degeneration. Nat Med. 2002;8(7):718-724.
6. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116(9):1599-1603.
7. Böcker-Meffert S, Rosenstiel P, Röhl C, et al. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci. 2002;43(6):2021-2026.
8. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49(12):5177-5182.
9. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):1061-1063.
10. Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118(7):1227-1228.
11. Haigh JJ. Role of VEGF in organogenesis. Organogenesis. 2008; 4(4):247-256.
12. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. Published online September 29, 2011.
13. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. Published online September 27, 2011.